Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and CD30 CAR-T in r/r CD30+ Lymphoma
NCT05320081Phase 2Unknown
- Sponsor
- Huazhong University of Science and Technology
- Start
- Nov 2021
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ATLCAR.CD30 T cells and camrelizumab in lymphoma, sponsored by Huazhong University of Science and Technology. Primary endpoints: Overall Response Rate at 3 months and Adverse Events at 90 days. Status: unknown.
02
Drugs
ATLCAR.CD30 T cellscamrelizumab
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT05320081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05320081.